Login to Your Account

FDA hits clinics as Gottlieb addresses regenerative med

By Mark McCarty
Regulatory Editor

Monday, August 28, 2017

The FDA is working under a congressional mandate to adopt a more nimble approach to regulation of regenerative medicine, and the agency has responded with enforcement action against multiple clinics even as FDA Commissioner Scott Gottlieb announced that the agency will “advance a comprehensive policy framework” for regenerative medicine before the end of the calendar year.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription